Pfizer Covid-19 vaccine to have differential pricing across countries



Global pharma major has said it will have differential pricing on its COVID-19 vaccine for different countries, as the company aims to make the vaccine available across the world.


The company’s Indian arm has sought emergency use authorisation (EUA) for the Pfizer/BioNTech vaccine against COVID-19 in the country fromthe Indian drug regulator.



After the UK approval for the vaccine, and BioNTech are anticipating further regulatory decisions across the globe in the coming days and are ready to deliver vaccine doses following potential regulatory authorisations or approvals,had earlier said.


“The fundamental that went into the pricing was that we make sure we make it very quickly available to everyone,” Pfizer Inc Chairman and CEO Albert Bourla said at a virtual press conference organised by International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on Tuesday.


“We are having a tier pricing. It is one price for the developed world based on their GDP, another price, lower for the middle-income countries and in the low-income countries, like countries in Africa etc we are giving it on a not-on-profit base,” he added.


Even in developed countries, the price is what they can afford to pay. In the US the price is USD 19.50, the price of an average meal, Bourla said.


The company is in talks with various governments for the vaccine, he added.


Bourla also said the company is also working on a new formulation that will be able to avoid the -70 degree requirement and can be stored in simple refrigeration.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link

Leave a Comment

Your email address will not be published. Required fields are marked *